Lineage, Immunomic to develop glioblastoma immunotherapy

By The Science Advisory Board staff writers

April 20, 2021 -- Lineage Cell Therapeutics and Immunomic Therapeutics have signed a worldwide license and development collaboration agreement to generate a novel candidate derived from Lineage's VAC allogeneic cancer immunotherapy platform, which targets a proprietary, tumor-associated antigen construct provided by Immunomic for the treatment of glioblastoma multiforme.

The VAC platform is used to produce allogeneic, modified dendritic cells derived from pluripotent stem cells. The platform can be modified to carry selected antigens, including patient-specific tumor neo-antigens or viral antigens.

Lineage and Immunomic will collaborate on the manufacturing and clinical development of the novel VAC product candidate. Following development and delivery of current good manufacturing practice (cGMP) VAC product material, Immunomic will assume full and independent clinical and commercial responsibility for further advancement of the program.

Under the agreement, Lineage will be entitled to upfront payments totaling $2 million in the first year and up to $87 million in development and commercial milestones across multiple indications and territories. Lineage will also be eligible to receive royalties up to 10% on net sales of future products.

Lineage improves manufacturing of allogenic cell therapy product
Lineage Cell Therapeutics has provided an update for its OPC1 cell therapy program, an oligodendrocyte progenitor cell transplant for the treatment of...
Immunomic, Colmmune partner on cancer immunotherapy
Immunomic Therapeutics and CoImmune Therapeutics have entered into a license agreement for Immunomic to use CoImmune's proprietary dendritic cell process...
Lineage Cell, Cancer Research U.K. advance cancer vaccine
Lineage Cell Therapeutics and partner Cancer Research U.K. have posted positive preliminary phase I results from an ongoing study of VAC2 in non-small...
ITI, Replicate Bioscience partner on RNA technologies
Immunomic Therapeutics (ITI) and Replicate Bioscience have entered into a research and licensing option agreement to combine their technologies to combat...
Immunomic Therapeutics inks license deal with Ichor
Immunomic Therapeutics (ITI) has signed a licensing agreement with Ichor Medical Systems to support the development of its ITI-1001 investigational plasmid...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter